Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.37), $0.29 worse than the analyst estimate of ($1.08). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $41.46 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Bernstein sees downside risk to Apple's December quarter results
• Stifel Starts Jenoptik AG (JEN:GR) at Buy